Comments on: “Dodgeball” at Merck https://www.overlawyered.com/2005/11/dodgeball-at-merck/ Chronicling the high cost of our legal system Sun, 13 Nov 2005 12:03:22 +0000 hourly 1 By: Ted https://www.overlawyered.com/2005/11/dodgeball-at-merck/comment-page-1/#comment-1532 Sun, 13 Nov 2005 12:03:22 +0000 http://overlawyered.com/wpblog/?p=2781#comment-1532 You state this like it’s a proven lie, when it’s nothing of the sort. E.g., T.R. Hegi, et al., “Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac”, Br J Anaesth 2004; 92: 523–31. I suspect the studies you’re referring to are those that commend COX-2 inhibitors as an alternative to NSAIDs, because, unlike NSAIDs, the COX-2s don’t inhibit platelet aggregation, which would be an undesirable side effect in post-operative settings.

In any event, Mark Lanier aren’t using the “Dodgeball” document because it took a reasonable position in training lay Merck representatives the appropriate soundbites for responding to questions, but because it’s titled “Dodgeball.”

]]> By: David Vander Ploeg https://www.overlawyered.com/2005/11/dodgeball-at-merck/comment-page-1/#comment-1531 Thu, 10 Nov 2005 18:08:25 +0000 http://overlawyered.com/wpblog/?p=2781#comment-1531 When PointofLaw read the Dodgeball pamphlet, did he know the pharmacological effects of Cox-2’s on platelet aggregation? Starting in the mid 90’s, multiple studies show that Cox-2’s cause platelet aggregation. Keeping this in mind, I present the following Dodgeball excerpt:
“Question: If the physician is concerned about a potential increase in the risk for MI, how would you respond?
Answer: Doctor, once daily VIOXX has no effect on platelet aggregation.”

]]>